Cimbro, E, Dessi, M, Ziranu, P, Madeddu, C, Atzori, F, Lai, E, Pretta, A, Mariani, S, Donisi, C, Spanu, D, Pozzari, M, Murgia, S, Saba, G, Codipietro, C, Palmas, E, Sanna, G, Semonella, F, Sardo, S, Finco, G and Scartozzi, M (2024) Early taxane exposure and neurotoxicity in breast cancer patients. Supportive Care in Cancer, 32 (10). ISSN 0941-4355

Preview

Text Early taxane exposure and neurotoxicity in breast cancer patients.pdf - Published Version Available under License Creative Commons Attribution. Download (770kB) | Preview

Abstract

Introduction Breast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. Taxanes are the most used chemotherapeutic agents and are strictly connected to neurotoxicity. Taxane-induced neuropathy (TIN) significantly impacts patients’ quality of life (QOL). Early identification and management of TIN could improve preventive strategies to preserve patients’ QOL during and after breast cancer treatment. Objective This prospective, observational study aimed to evaluate the taxane-induced neuropathy (TIN) in early breast cancer patients treated with weekly paclitaxel at an earlier stage and identify any correlation between TIN and QOL. Methods Data from stage I-III breast cancer patients treated with taxane-based therapy between 2018 and 2022 were collected at the Medical Oncology Unit of the University Hospital of Cagliari. Peripheral neuropathy was evaluated using the NCI-CTCAE scale (National Cancer Institute, Common Terminology Criteria for Adverse Events) at every drug administration. In contrast, QOL was assessed using EORTC QLC-CIPN20 and FACT-Taxane questionnaire at baseline (T0), after 4 weeks (T1) and 12 (T2) weeks of treatment. Statistical analysis was performed to evaluate the correlation between neurotoxicity and QOL. Results Neurotoxicity incidence peaked at the third, fourth, and sixth week of treatment, with patients reporting grade 1 and 2 neurotoxicity. Simultaneously with increasing doses of paclitaxel, significant differences in QOL were observed in early treatment cycles relating to TIN presentation. Patients with higher neurotoxicity grades reported lower QOL scores. Conclusions Despite the absence of effective treatments to prevent paclitaxel-induced neurotoxicity, symptoms are managed through dosage reduction, delay, or treatment interruption. Future research should focus on identifying neuroprotective measures to avoid an irreversible decline in the quality of life for breast cancer survivors.

Item Type:	Article
Uncontrolled Keywords:	Taxane; Neurotoxicity; Quality of life; Humans; Breast Neoplasms; Peripheral Nervous System Diseases; Neurotoxicity Syndromes; Taxoids; Paclitaxel; Antineoplastic Agents, Phytogenic; Prospective Studies; Quality of Life; Adult; Aged; Middle Aged; Female; Bridged-Ring Compounds; Neurotoxicity; Quality of life; Taxane; Humans; Female; Breast Neoplasms; Quality of Life; Middle Aged; Prospective Studies; Neurotoxicity Syndromes; Paclitaxel; Aged; Peripheral Nervous System Diseases; Adult; Taxoids; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Neurosciences; Clinical Research; Peripheral Neuropathy; Breast Cancer; Neurodegenerative; Women's Health; Cancer; Prevention; Patient Safety; Cancer; Humans; Female; Breast Neoplasms; Quality of Life; Middle Aged; Prospective Studies; Neurotoxicity Syndromes; Paclitaxel; Aged; Peripheral Nervous System Diseases; Adult; Taxoids; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; 11 Medical and Health Sciences; 17 Psychology and Cognitive Sciences; Oncology & Carcinogenesis
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Biological and Environmental Sciences (from Sep 19)
Publisher:	Springer
SWORD Depositor:	A Symplectic
Date Deposited:	28 Nov 2024 10:09
Last Modified:	28 Nov 2024 10:15
DOI or ID number:	10.1007/s00520-024-08908-2
URI:	https://researchonline.ljmu.ac.uk/id/eprint/24900

View Item